Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19
- PMID: 32186711
- PMCID: PMC7184445
- DOI: 10.1093/jtm/taaa041
Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19
Abstract
Intravenous infusions of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in experimental animals increase the numbers of angiotensin-converting enzyme 2 (ACE2) receptors in the cardiopulmonary circulation. ACE2 receptors serve as binding sites for SARS-CoV-2 virions in the lungs. Patients who take ACEIs and ARBS may be at increased risk of severe disease outcomes due to SARS-CoV-2 infections.
Comment in
-
Keep taking your ACE inhibitors and ARBs during the COVID 19 pandemic.J Travel Med. 2020 May 18;27(3):taaa045. doi: 10.1093/jtm/taaa045. J Travel Med. 2020. PMID: 32268374 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous